Leerink Partnrs Upgrades Benitec Biopharma (NASDAQ:BNTC) to “Strong-Buy”

Leerink Partnrs upgraded shares of Benitec Biopharma (NASDAQ:BNTC) to a strong-buy rating in a report published on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($5.45) EPS, FY2025 earnings at ($1.81) EPS and FY2026 earnings at ($1.83) EPS.

Other equities analysts have also recently issued reports about the company. Piper Sandler initiated coverage on Benitec Biopharma in a report on Thursday, June 13th. They issued an overweight rating and a $30.00 price objective for the company. JMP Securities increased their price target on shares of Benitec Biopharma from $10.00 to $16.00 and gave the company a market outperform rating in a research report on Monday, April 22nd. Finally, SVB Leerink started coverage on shares of Benitec Biopharma in a research note on Monday. They set an outperform rating and a $13.00 price target on the stock.

Benitec Biopharma Trading Down 1.5 %

Shares of BNTC opened at $9.13 on Monday. Benitec Biopharma has a 1-year low of $1.86 and a 1-year high of $10.88. The company has a market capitalization of $85.55 million, a P/E ratio of -4.91 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.18 and a quick ratio of 4.18. The firm’s 50 day simple moving average is $8.36 and its 200 day simple moving average is $6.16.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) EPS for the quarter. Sell-side analysts forecast that Benitec Biopharma will post -6.56 earnings per share for the current fiscal year.

Institutional Trading of Benitec Biopharma

A hedge fund recently raised its stake in Benitec Biopharma stock. Janus Henderson Group PLC raised its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 244,491 shares of the biotechnology company’s stock after buying an additional 64,092 shares during the period. Janus Henderson Group PLC owned about 9.44% of Benitec Biopharma worth $1,266,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.